Marjorie Labesse
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Marjorie Labesse has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Adeline Bouard
Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, Besançon, France
13 shared publications - Alexandre Harari
Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland
13 shared publications - Angélique Vienot
Department of medical oncology, University Hospital of Besançon, Besançon, France
13 shared publications - Camilla Jandus
Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland
13 shared publications - Charles-Frédéric Mantion
Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, Besançon, France
13 shared publications - Christophe Borg
Department of Medical Oncology, Centre Hospitalier Universitaire de Besançon, Besançon, France; Clinical Investigational Centre, CIC-1431, Centre Hospitalier Universitaire de Besançon, Besançon, France; Université Marie et Louis Pasteur, Établissement Français du Sang, INSERM UMR1098 RIGHT, Besançon, France
13 shared publications
Latest Publications
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
Supplementary Table S1. Homology of SALL4-derived S9V peptide sequence in human proteome
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
Supplementary Table S1. Homology of SALL4-derived S9V peptide sequence in human proteome
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
Immunophenotyping profile of SALL4-TCR T cells. (A) Memory phenotype: TN/TSCM (CD45RA+, CD62L+), TEMRA (CD62L-, CD45RA+), TCM (CD62L+, CD45RA-) and TEM (CD45RA-, CD62L-) subset distribution in unstimulated and S9V stimulated primary T cells redirected to express SALL4-TCR (n=4). (B) t-SNE representation of the expression of extracellular activation markers and immune checkpoint molecules (CD69, HLA-DR, 4-1BB, PD1, LAG3, and TIM3) of unstimulated and stimulated SALL4-TCR T cells. (C) Expression of CD69, HLA-DR, 4-1BB, PD1, LAG3, and TIM3 on unstimulated and stimulated SALL4-TCR T cells. (D) Co-expression of pairs of checkpoint markers (PD1, TIM3, LAG3, and TIGIT). (E) Expression of chemokine receptors CXCR2, CXCR3, CXCR4, CXCR6, CX3CR1 and CCR4 on SALL4-TCR T cells. (F) Quantification of released analytes including TNF-α, IFNγ, granzyme A, granzyme B, IL2, IL4, and perforin assessed by Legendplex analysis in cell culture supernatants of SALL4-TCR T cells previously stimulated or not during 5h with S9V peptide at different concentration [0-10µg/mL] (n = 4).
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
Immunophenotyping profile of SALL4-TCR T cells. (A) Memory phenotype: TN/TSCM (CD45RA+, CD62L+), TEMRA (CD62L-, CD45RA+), TCM (CD62L+, CD45RA-) and TEM (CD45RA-, CD62L-) subset distribution in unstimulated and S9V stimulated primary T cells redirected to express SALL4-TCR (n=4). (B) t-SNE representation of the expression of extracellular activation markers and immune checkpoint molecules (CD69, HLA-DR, 4-1BB, PD1, LAG3, and TIM3) of unstimulated and stimulated SALL4-TCR T cells. (C) Expression of CD69, HLA-DR, 4-1BB, PD1, LAG3, and TIM3 on unstimulated and stimulated SALL4-TCR T cells. (D) Co-expression of pairs of checkpoint markers (PD1, TIM3, LAG3, and TIGIT). (E) Expression of chemokine receptors CXCR2, CXCR3, CXCR4, CXCR6, CX3CR1 and CCR4 on SALL4-TCR T cells. (F) Quantification of released analytes including TNF-α, IFNγ, granzyme A, granzyme B, IL2, IL4, and perforin assessed by Legendplex analysis in cell culture supernatants of SALL4-TCR T cells previously stimulated or not during 5h with S9V peptide at different concentration [0-10µg/mL] (n = 4).
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
SALL4-TCR T cells recognize natural SALL4+ cancer cell lines in an HLA-A2 restricted manner.
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
SALL4-TCR T cells recognize natural SALL4+ cancer cell lines in an HLA-A2 restricted manner.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
Expression of SALL4-TCR in Jurkat TCR KO CD8+ T cells via mRNA electroporation. Representative FACS SALL4-teramer staining on Jurkat TCR KO CD8+ T cells electroporated with mRNA encoding α and β subunits for the SALL4-TCR (right) or an irrelevant-TCR (middle). Mock electroporated cells (no mRNA, left) were used for negative control.
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
Expression of SALL4-TCR in Jurkat TCR KO CD8+ T cells via mRNA electroporation. Representative FACS SALL4-teramer staining on Jurkat TCR KO CD8+ T cells electroporated with mRNA encoding α and β subunits for the SALL4-TCR (right) or an irrelevant-TCR (middle). Mock electroporated cells (no mRNA, left) were used for negative control.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
Supplementary Table S2: List of antibodies and flow cytometry regents used
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
Supplementary Table S2: List of antibodies and flow cytometry regents used
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
SALL4-TCR T cells exhibit anti-tumor activity in vivo.
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
SALL4-TCR T cells exhibit anti-tumor activity in vivo.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
SALL4-derived S9V specific CD8+ T clone recognize and kill MDA-MB231-SALL4 cell line in vitro. Mean number of IFN-γ (left) and GZMB (right) spots counted on ELISpot upon 24h coculture of SALL4 specific CD8+ T clone with MDA-MB231-SALL4 with different E:T ratio 10:1, 5:1, 1:1, 1:5 and 1:10. Data represent mean ± SD of duplicates. Responses were considered positive if the number of SFC was > 10 spots/104 T clone and 2 times the background value. MDA-MB231-CTRL cell line transduced with empty lentiviral vector was used as negative control. Anti MHC-I antibody was used for specific T cell restriction reactivation validation.
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
SALL4-derived S9V specific CD8+ T clone recognize and kill MDA-MB231-SALL4 cell line in vitro. Mean number of IFN-γ (left) and GZMB (right) spots counted on ELISpot upon 24h coculture of SALL4 specific CD8+ T clone with MDA-MB231-SALL4 with different E:T ratio 10:1, 5:1, 1:1, 1:5 and 1:10. Data represent mean ± SD of duplicates. Responses were considered positive if the number of SFC was > 10 spots/104 T clone and 2 times the background value. MDA-MB231-CTRL cell line transduced with empty lentiviral vector was used as negative control. Anti MHC-I antibody was used for specific T cell restriction reactivation validation.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
SALL4-TCR T cells do not recognize human hematopoietic stem cells CD34+ in vivo. (A) Schematic outlining the experimental procedure of adoptive T cell transfer in hNSG mice. hNSG mice were engrafted IV with 107 Mock (n=9) or SALL4-TCR transduced T cells (n=10) or not (n=8). Seven days after injection, mice were sacrificed and BM were collected. Blood samples were harvested at day 0 before T cells injection and at day 7 following T cell injection. (B) Flow cytometry gating strategy in BM (left) and in the blood samples (right). (left) HSC were determined by the expression of CD34 and CD38 among human CD45 cells. Dendritic cell (DC), in pink, were determined by the medium expression on CD33 and medium expression of CD123, HLA-DR and CD303. Monocytes, in blue, were determined by the high expression of CD33, medium expression on HLA-DR, CD123 and CD303. (right) The percentage of humanization is determined by the ratio mCD45/hCD45. Monocytes were selected from human cells (hCD45+) based on the expression of CD33 and CD14. (C) and (D) Flow cytometry analyses of HSC and myeloid-derived differentiated cells in BM (C) and monocytes in blood (D) among hCD45 cells.
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
SALL4-TCR T cells do not recognize human hematopoietic stem cells CD34+ in vivo. (A) Schematic outlining the experimental procedure of adoptive T cell transfer in hNSG mice. hNSG mice were engrafted IV with 107 Mock (n=9) or SALL4-TCR transduced T cells (n=10) or not (n=8). Seven days after injection, mice were sacrificed and BM were collected. Blood samples were harvested at day 0 before T cells injection and at day 7 following T cell injection. (B) Flow cytometry gating strategy in BM (left) and in the blood samples (right). (left) HSC were determined by the expression of CD34 and CD38 among human CD45 cells. Dendritic cell (DC), in pink, were determined by the medium expression on CD33 and medium expression of CD123, HLA-DR and CD303. Monocytes, in blue, were determined by the high expression of CD33, medium expression on HLA-DR, CD123 and CD303. (right) The percentage of humanization is determined by the ratio mCD45/hCD45. Monocytes were selected from human cells (hCD45+) based on the expression of CD33 and CD14. (C) and (D) Flow cytometry analyses of HSC and myeloid-derived differentiated cells in BM (C) and monocytes in blood (D) among hCD45 cells.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
SALL4-TCR redirected T cells recognize and kill S9V preloaded MDA-MB231 cell line (positive control). Representative graphs of Mock or SALL4-TCR T cells cocultured during 2 days with MDA-MB231 cell line preloaded with S9V peptide. (A) In vitro lysis kinetics obtained by red cytotox (left) and green signal (right) measurements on S9V preloaded MDA-MB231 during 2 days coculture in the presence of Mock (orange) or SALL4-TCR T cells (blue) measured by live-cell imaging IncuCyte. E:T ratio 10:1. Data represent mean ± SD of triplicates, statistics were calculated on the 3000 min time point. ***p<0.0001. (B) Representative pictures where green signals come from GFP, red signals come from red cytotoxic dye measured by live-cell imaging IncuCyte. E:T ratio 10:1. Scale bar, 400nm.
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
SALL4-TCR redirected T cells recognize and kill S9V preloaded MDA-MB231 cell line (positive control). Representative graphs of Mock or SALL4-TCR T cells cocultured during 2 days with MDA-MB231 cell line preloaded with S9V peptide. (A) In vitro lysis kinetics obtained by red cytotox (left) and green signal (right) measurements on S9V preloaded MDA-MB231 during 2 days coculture in the presence of Mock (orange) or SALL4-TCR T cells (blue) measured by live-cell imaging IncuCyte. E:T ratio 10:1. Data represent mean ± SD of triplicates, statistics were calculated on the 3000 min time point. ***p<0.0001. (B) Representative pictures where green signals come from GFP, red signals come from red cytotoxic dye measured by live-cell imaging IncuCyte. E:T ratio 10:1. Scale bar, 400nm.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
SALL4 induction in cancer cell by 5-azacytidine modulates SALL4-TCR T cells activation. (A) Expression of SALL4 detected by qRT-PCR (top) and Western blotting (bottom) (Sall4 Antibody (G-3): sc-166033 Santa Cruz) for MDA-MB231 treated with 5-azacytidine (5-aza) (2µM) for 72h and 6 days. (B) Degranulation (CD107a) stainings assessed by flow cytometry comparing Mock and SALL4-TCR T cells for their SALL4 reactivity upon coculture with MDA-MB231 treated 72h and 6 Days with 5-Aza. T cells were cocultured for 5h at E:T ratio 1:50 for n=3 different HDs, mean ±SEM. Anti-HLA-A2 (BB7.2) were used for specific reactivity controls. Statistics were calculated using ANOVA test, *p<0.05, ***p<0.001. (C) Relative mRNA expression levels of SALL4 in cancer cell lines pretreated or not with 5-aza (2µM) for 72h. (D) Intracellular TNF-α staining assessed by flow cytometry analysis comparing Mock and SALL4-TCR T cells for their SALL4 reactivity upon coculture with cancer cell lines treated 48h before the coculture with IFN-γ (200UI/mL) and 72 h with 5-aza (2µM) or not. T cells were cocultured for 16h at E:T ratio 1:20. (E) Anti-MHC-I (W6/32) or isotype antibody were used for specific reactivity controls. Cell lines were not treated prior the coculture. HeLa, A2780 and HUH-7 were transduced to express HLA-A2.
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
SALL4 induction in cancer cell by 5-azacytidine modulates SALL4-TCR T cells activation. (A) Expression of SALL4 detected by qRT-PCR (top) and Western blotting (bottom) (Sall4 Antibody (G-3): sc-166033 Santa Cruz) for MDA-MB231 treated with 5-azacytidine (5-aza) (2µM) for 72h and 6 days. (B) Degranulation (CD107a) stainings assessed by flow cytometry comparing Mock and SALL4-TCR T cells for their SALL4 reactivity upon coculture with MDA-MB231 treated 72h and 6 Days with 5-Aza. T cells were cocultured for 5h at E:T ratio 1:50 for n=3 different HDs, mean ±SEM. Anti-HLA-A2 (BB7.2) were used for specific reactivity controls. Statistics were calculated using ANOVA test, *p<0.05, ***p<0.001. (C) Relative mRNA expression levels of SALL4 in cancer cell lines pretreated or not with 5-aza (2µM) for 72h. (D) Intracellular TNF-α staining assessed by flow cytometry analysis comparing Mock and SALL4-TCR T cells for their SALL4 reactivity upon coculture with cancer cell lines treated 48h before the coculture with IFN-γ (200UI/mL) and 72 h with 5-aza (2µM) or not. T cells were cocultured for 16h at E:T ratio 1:20. (E) Anti-MHC-I (W6/32) or isotype antibody were used for specific reactivity controls. Cell lines were not treated prior the coculture. HeLa, A2780 and HUH-7 were transduced to express HLA-A2.